PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Neurocrine Biosciences Inc | NBIX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -2.38 | -2.15% | 108.53 | 111.38 | 108.27 | 110.15 | 110.91 | 11:53:50 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 108.51 | 108.60 | 0.09 | 0.08% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,993 | 318,820 | $ 109.39 | $ 34,876,612 | 685,729 | 62.00 - 113.12 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:53:50 | 14 | $ 108.53 | USD |
Neurocrine Biosciences Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 9.99B | 92.09M | $ 21.11M | 0.17 | 619.40 | 90.03M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Neurocrine Biosciences News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/13/2019 | 16:42 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/13/2019 | 16:37 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/12/2019 | 16:01 | PR Newswire (US) | Neurocrine Biosciences Publishes Long-Term INGREZZA®.. |
| 11/05/2019 | 16:39 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/05/2019 | 16:38 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/05/2019 | 16:01 | PR Newswire (US) | Neurocrine Biosciences to Present at Upcoming Healthcare.. |
| 11/05/2019 | 06:01 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NBIX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 102.98 | 113.12 | 102.79 | 110.05 | 960,662 | 5.55 | 5.39% |
| 1 Month | 94.42 | 113.12 | 93.60 | 102.57 | 794,483 | 14.11 | 14.94% |
| 3 Months | 98.56 | 113.12 | 84.675 | 97.93 | 664,682 | 9.97 | 10.12% |
| 6 Months | 77.06 | 113.12 | 75.90 | 92.26 | 649,456 | 31.47 | 40.84% |
| 1 Year | 99.01 | 113.12 | 62.00 | 85.36 | 858,667 | 9.52 | 9.62% |
| 3 Years | 52.79 | 126.98 | 37.345 | 73.54 | 896,351 | 55.74 | 105.59% |
| 5 Years | 19.16 | 126.98 | 18.37 | 60.76 | 909,122 | 89.37 | 466.44% |
Neurocrine Biosciences Description
| Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. |
